IN UTERO EXPOSURE TO ANTI-NAUSEA DRUG SHOWN TO INCREASE RISK OF ADULT-ONSET COLORECTAL CANCER

Prenatal exposure to an anti-nausea drug commonly used in the 1960s and 1970s has been shown to increase risk of colorectal cancer in adult offspring, according to a study by researchers at UTHealth Houston.this is..

The study, led by Caitlin Murphy, PhD, MPH, associate professor at UTHealth Houston School of Public Health, was published today in JNCI Cancer Spectrum.

Incidence rates of colorectal cancer are increasing among adults born in and after the 1960s, which Murphy said implicates pregnancy-related exposures introduced at that time as risk factors. Dicyclomine – used to treat spasms caused by irritable bowel syndrome – was initially included in Bendectin, a drug prescribed during pregnancy in the 1960s to prevent nausea and vomiting.

After reports of birth defects and concerns in the wake of the thalidomide tragedy, the manufacturer removed dicyclomine from the drug's formula in 1976. Pregnant women in the late 1950s and early 1960s were prescribed a drug containing thalidomide to relieve morning sickness, which led to a scandal when more than 10,000 offspring were born with a range of severe deformities.

Still, Murphy said experimental studies are needed to clarify these findings and identify mechanisms of risk.

"Dicyclomine is still used in clinical practice to treat irritable bowel syndrome. It is designated as Pregnancy Category B by the U.S. Food and Drug Administration, meaning there are not adequate studies of pregnant women to determine risk to the fetus," she said. "Medications prescribed to pregnant women may contribute to higher rates of cancer among offspring exposed in the womb."

Barbara A. Cohn, PhD, with the Public Health Institute in Berkeley, California, was senior author of the study. Co-authors from the Public Health Institute were Piera M. Cirillo, MPH, and Nickilou Y. Krigbaum, MPH. Amit G. Singal, MD, with UT Southwestern Medical Center in Dallas, also contributed.